Please turn JavaScript on
European Biotechnology Magazine icon

European Biotechnology Magazine

Subscribe to European Biotechnology Magazine’s news feed.

Click on “Follow” and decide if you want to get news from European Biotechnology Magazine via RSS, as email newsletter, via mobile or on your personal news page.

Subscription to European Biotechnology Magazine comes without risk as you can unsubscribe instantly at any time.

You can also filter the feed to your needs via topics and keywords so that you only receive the news from European Biotechnology Magazine which you are really interested in. Click on the blue “Filter” button below to get started.

Website title: European Biotechnology Magazine

Is this your feed? Claim it!

Publisher:  Unclaimed!
Message frequency:  2.63 / day

Message History

This week in our news roundup: Cellectis’ shift toward in vivo gene editing comes with steep workforce cuts, while Sanofi and AstraZeneca add new technologies through deals. Elsewhere, respiratory developers plan a merger, Lithuania’s Biomatter raises funding and Zealand seeks partners for its rare-disease medicines.

The post


Read full story

Danish biotech Commit Biologics has completed a $60 million (€54 million) seed financing round to advance its first complement-powered immune engager toward clinical trials. The closing follows the nomination of its first drug candidate and several senior appointments as the company prepares to enter the clinic.

The post


Read full story

Cambridge-based TRIMTECH Therapeutics has signed a research collaboration and licensing option agreement with Biogen to develop small-molecule protein degraders for neurodegenerative diseases. The deal could bring TRIMTECH up to $411 million (about €373 million), plus royalties.

The post


Read full story

Three developments over the past year have changed what “outsourcing” a clinical trial actually means. New U.S. tariffs on patented pharmaceuticals, a revised Chinese trial standard, and faster approval rules in Europe, the UK and ­Australia are all forcing sponsors to look again at where trials run and who runs them.

The post


Read full story

U.S. biotech venture creator Flagship Pioneering is investing an initial £100 million (€120 million) to establish an AI-focused company-creation lab in London, marking the first expansion of its company-building model outside the United States.

The post


Read full story